-

06:28:43 PM

SESN Stock News

SESN - Sesen Bio Inc.

09/21/22 8:00 AM

Nasdaq : SESN

acquisition

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

Combined company expected to have approximately $180 million of cash, cash equivalents and marketable securities at close, including $30 million from a concurrent financing by Carisma, which is expected to fund the combined company through 2024. Cash runway of combined company expected to enable multiple clinical readouts across Carisma programs.

RHEA-AI

positive

08/08/22 8:00 AM

Nasdaq : SESN

earnings

Sesen Bio Reports Second Quarter 2022 Financial Results and Business Update

Sesen Bio today reported operating results for the second quarter ended June 30, 2022. On July 11, 2022, Sesen Bio participated in a Type B Meeting with the US Food and Drug Administration. During the meeting, the Company and the FDA discussed outstanding items related to the Company' s proposed protocol and statistical analysis plan design elements for an...

RHEA-AI

neutral

07/18/22 7:30 AM

Nasdaq : SESN

clinical trial

Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum(TM) in the US

Sesen Bio today announced that it has made the strategic decision to voluntarily pause further development in the US of its lead asset, Vicineum. This decision enables Sesen Bio to conserve cash while it continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Thomas Cannell, president and chief executive officer...

RHEA-AI

neutral

05/09/22 8:00 AM

Nasdaq : SESN

earnings

Sesen Bio Reports First Quarter 2022 Financial Results and Business Update

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the first quarter ended March 31, 2022. On March 28, 2022, Sesen Bio participated in a Type C Meeting with the FDA. On January 6, 2022, Sesen Bio disclosed that it achieved a $20 million...

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : SESN

Sesen Bio Provides Strategic Update

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that it has initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Thomas Cannell, president and chief executive officer of Sesen Bio." As we assess potential...

RHEA-AI

neutral

02/28/22 8:00 AM

Nasdaq : SESN

earnings

Sesen Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Anticipated Regulatory Path Forward for the Company's Lead Product Candidate, Vicineum(TM)

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the fourth quarter and full year ended December 31, 2021. Thomas Cannell, president and chief executive officer of Sesen Bio." We have bolstered our team' s expertise in order to carry out that...

RHEA-AI

neutral

01/10/22 8:00 AM

Nasdaq : SESN

Sesen Bio Further Enhances Team with Key Hires

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointments of Minori Rosales, M.D., Ph.D. as Chief Development Officer as of January 24, 2022 and Stephanie Vigue as Director of Finance as of January 17, 2022. Thomas Cannell, president and chief executive...

RHEA-AI

very positive

12/09/21 8:00 AM

Nasdaq : SESN

Sesen Bio Announces Anticipated Regulatory Path Forward for Vicineum(TM)

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced its anticipated regulatory path forward for Vicineum(TM) for the treatment of BCG-unresponsive non-muscle invasive bladder cancer following its Clinical Type A meeting with the US Food and Drug...

RHEA-AI

neutral

11/29/21 8:00 AM

Nasdaq : SESN

Sesen Bio Strengthens Medical Team

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the strengthening of its medical team with the hiring of Dominika Kowalski as Senior Director of Global Drug Safety. Thomas Cannell, president and chief executive officer of Sesen Bio." Dominika has the right...

RHEA-AI

very positive

11/23/21 8:00 AM

Nasdaq : SESN

Sesen Bio Director Jane Pritchett Henderson Transitions to CEO Advisor Role

Sesen Bio, a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Jane Pritchett Henderson, previously a member of Sesen Bio' s Board of Directors and the Chair of the Board' s Audit Committee, has transitioned off the Board of Directors to a CEO Advisor role, effective...

RHEA-AI

neutral

1 2 3 4 5 6 Next

SESN Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.sesenbio.com
CeoThomas Cannell
Security nameSesen Bio Inc.
Issue typecs
SectorManufacturing
Sic code2834
Employees27
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address245 1st St Ste 1800
StateMassachusetts
CityCambridge
Zip02142-1292
CountryUS
Phone16174448550

About Sesen Bio Inc.

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company's lead program, Vicineum™, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2020, the Company completed the BLA submission for Vicineum to the FDA. Sesen Bio retains worldwide rights to Vicineum with the exception of Greater China and the Middle East and North Africa (MENA), for which the Company has partnered with Qilu Pharmaceutical and Hikma Pharmaceuticals, respectively, for commercialization. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC.